(Q46467683)

22 December 2017

title

Immunohistochemical profiles of brain metastases from breast cancer (English)

1 reference

22 December 2017

1 reference

1 reference

3

Chikako Shimizu

1 reference

22 December 2017

Yasuhiro Fujiwara

12

object named as

Yasuhiro Fujiwara

1 reference

22 December 2017

Kan Yonemori

1

object named as

Kan Yonemori

1 reference

22 December 2017

author name string

Koji Tsuta

2

1 reference

22 December 2017

Yutaka Hatanaka

4

1 reference

22 December 2017

Kaoru Hashizume

5

1 reference

22 December 2017

Makiko Ono

6

1 reference

22 December 2017

Yukihiro Nakanishi

7

1 reference

22 December 2017

Tadashi Hasegawa

8

1 reference

22 December 2017

Yasuji Miyakita

9

1 reference

22 December 2017

Yoshitaka Narita

10

1 reference

22 December 2017

Soichiro Shibui

11

1 reference

22 December 2017

publication date

23 July 2008

1 reference

22 December 2017

Journal of Neuro-Oncology

published in

1 reference

22 December 2017

volume

90

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

223-228

1 reference

22 December 2017

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-008-9654-X

Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-008-9654-X

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-008-9654-X

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

21 January 2018

1 reference

12 December 2020

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

1 reference

12 December 2020

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

1 reference

12 December 2020

Primary breast cancer phenotypes associated with propensity for central nervous system metastases

1 reference

12 December 2020

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer

1 reference

12 December 2020

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

12 December 2020

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Triple-negative breast cancer: therapeutic options

1 reference

12 December 2020

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

12 December 2020

HER-2/neu expression in primary and metastatic breast cancer

1 reference

12 December 2020

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

12 December 2020

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

12 December 2020

CNS metastases in breast cancer

1 reference

12 December 2020

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

12 December 2020

HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

1 reference

12 December 2020

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

12 December 2020

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy

1 reference

12 December 2020

10.1007/S11060-008-9654-X

Identifiers

DOI

1 reference

22 December 2017

release_lxkt2x7mdbg5jezviahc5khh3i

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lxkt2x7mdbg5jezviahc5khh3i

24 November 2022

mapped directly with Wikidata item

1 reference

22 December 2017